News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
306,007 Results
Type
Article (30216)
Company Profile (106)
Press Release (275685)
Section
Business (80331)
Career Advice (296)
Deals (12277)
Drug Delivery (44)
Drug Development (47518)
Employer Resources (39)
FDA (6518)
Job Trends (6518)
News (144961)
Policy (11858)
Tag
2024 BioCapital Digital (5)
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (3)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (1)
2026 Biotech Bay Standard (1)
Academia (2030)
Academic (1)
Accelerated approval (1)
Adcomms (17)
Allergies (16)
Alliances (24504)
ALS (35)
Alzheimer's disease (651)
Antibody-drug conjugate (ADC) (126)
Approvals (6539)
Artificial intelligence (135)
Autoimmune disease (8)
Automation (4)
Bankruptcy (98)
Best Places to Work (5645)
BIOSECURE Act (15)
Biosimilars (43)
Biotechnology (87)
Bladder cancer (62)
Brain cancer (27)
Breast cancer (268)
Cancer (2068)
Cardiovascular disease (51)
Career advice (274)
Career pathing (7)
CAR-T (132)
Cell therapy (303)
Cervical cancer (19)
Clinical research (37514)
Collaboration (456)
Compensation (143)
Complete response letters (10)
COVID-19 (1353)
CRISPR (22)
C-suite (106)
Cystic fibrosis (34)
Data (1106)
Decentralized trials (1)
Denatured (2)
Depression (5)
Diabetes (68)
Diagnostics (3940)
Digital health (4)
Diversity (4)
Diversity, equity & inclusion (13)
Drug discovery (58)
Drug pricing (44)
Drug shortages (4)
Duchenne muscular dystrophy (19)
Earnings (25599)
Editorial (9)
Employer branding (6)
Employer resources (35)
Events (48352)
Executive appointments (286)
FDA (7032)
Featured Employer (15)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (402)
Gene editing (42)
Generative AI (7)
Gene therapy (117)
GLP-1 (230)
Government (1886)
Guidances (18)
Healthcare (9200)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (48)
Indications (16)
Infectious disease (1404)
Inflammatory bowel disease (61)
Inflation Reduction Act (4)
Influenza (16)
Intellectual property (38)
Interviews (34)
IPO (6419)
IRA (23)
Job creations (1136)
Job search strategy (254)
Kidney cancer (10)
Labor market (9)
Layoffs (189)
Leadership (1)
Legal (1990)
Liver cancer (75)
Lung cancer (309)
Lymphoma (124)
Machine learning (1)
Management (11)
Manufacturing (103)
MASH (23)
Medical device (3688)
Medtech (3688)
Mergers & acquisitions (6072)
Metabolic disorders (167)
Multiple sclerosis (20)
NASH (5)
Neurodegenerative disease (16)
Neuropsychiatric disorders (4)
Neuroscience (793)
NextGen: Class of 2025 (2709)
Non-profit (2713)
Northern California (1204)
Now hiring (7)
Obesity (78)
Opinion (97)
Ovarian cancer (74)
Pain (27)
Pancreatic cancer (78)
Parkinson's disease (36)
Partnered (8)
Patents (74)
Patient recruitment (56)
Peanut (10)
People (25804)
Pharmaceutical (23)
Pharmacy benefit managers (4)
Phase I (13519)
Phase II (16494)
Phase III (11408)
Pipeline (521)
Podcasts (20)
Policy (60)
Postmarket research (1324)
Preclinical (5898)
Press Release (28)
Prostate cancer (96)
Psychedelics (13)
Radiopharmaceuticals (234)
Rare diseases (141)
Real estate (1988)
Recruiting (15)
Regulatory (8951)
Reports (17)
Research institute (2080)
Resumes & cover letters (27)
RNA editing (1)
RSV (14)
Schizophrenia (18)
Series A (64)
Series B (31)
Sickle cell disease (30)
Southern California (970)
Special edition (3)
Spinal muscular atrophy (51)
Sponsored (8)
Startups (1784)
State (1)
Stomach cancer (15)
Supply chain (15)
The Weekly (18)
United States (9903)
Vaccines (332)
Venture capitalists (16)
Webinars (3)
Weight loss (38)
Women's health (17)
Worklife (4)
Date
Last 7 days (324)
Last 30 days (1187)
Last 365 days (16732)
2025 (3713)
2024 (17580)
2023 (19975)
2022 (26042)
2021 (27389)
2020 (24809)
2019 (20484)
2018 (15222)
2017 (15214)
2016 (14755)
2015 (17165)
2014 (12931)
2013 (10511)
2012 (10715)
2011 (11149)
2010 (10302)
Location
Africa (295)
Alabama (32)
Alaska (4)
Arizona (79)
Arkansas (5)
Asia (20562)
Australia (3941)
California (2588)
Canada (822)
China (308)
Colorado (116)
Connecticut (128)
Delaware (85)
Europe (42724)
Florida (377)
Georgia (68)
Idaho (20)
Illinois (232)
India (13)
Indiana (133)
Iowa (3)
Japan (72)
Kansas (35)
Kentucky (18)
Louisiana (1)
Maine (12)
Maryland (366)
Massachusetts (1899)
Michigan (46)
Minnesota (131)
Missouri (44)
Montana (14)
Nebraska (9)
Nevada (8)
New Hampshire (40)
New Jersey (870)
New Mexico (13)
New York (876)
North Carolina (334)
North Dakota (6)
Northern California (1204)
Ohio (80)
Oklahoma (6)
Oregon (13)
Pennsylvania (473)
Puerto Rico (3)
Rhode Island (10)
South America (384)
South Carolina (6)
Southern California (970)
Tennessee (25)
Texas (512)
Utah (63)
Virginia (49)
Washington D.C. (39)
Washington State (327)
West Virginia (2)
Wisconsin (32)
306,007 Results for "dana farber cancer institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma.
November 9, 2023
·
5 min read
Business
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer
eFFECTOR Therapeutics, Inc. today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer.
May 20, 2024
·
6 min read
Genetown
Dana Farber Cancer Institute’s Jimmy Fund Celebrates 75 years of Progress and Impact on May 22
Dana-Farber Cancer Institute’s Jimmy Fund will launch its 75th anniversary on Monday, May 22. Activities will include adult and pediatric patients unveiling and previewing the Jimmy Fund inspired cow, “Strong as Iron,” from this summer’s CowParade New England presented by Herb Chambers art installation.
May 22, 2023
·
7 min read
Biotech Beach
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
LIXTE Biotechnology Holdings, Inc. announced it is co-sponsoring an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Institute on May 9 and 10, 2024 in Boston, Massachusetts.
May 8, 2024
·
4 min read
Genetown
Mass General Brigham and Dana-Farber Cancer Institute collaborating with BEEAH Group to advise on a new, patient-centered health care system
Mass General Brigham and Dana-Farber Cancer Institute are collaborating with BEEAH Group, an organization pioneering sustainability and quality of life solutions in the Middle East, to advise in the development the Jawaher Boston Medical District, a state-of-the-art health care system designed to deliver world-class, patient-centered care through innovation, technology, and sustainability.
May 12, 2023
·
6 min read
Business
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
ProPhase Labs, Inc. (NASDAQ: PRPH) today announced that its wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), and Dana-Farber Cancer Institute have entered into a two-year collaborative agreement to further the research and development of a small molecule, Linebacker-1 (LB-1), that is intended as a therapy enhancer for traditional chemotherapeutic agents to both increase efficacy and decrease toxicity in current cancer treatments.
November 8, 2022
·
8 min read
Pharm Country
Grant Awarded to Identify New Druggable Targets in Gastroesophageal Cancer
The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative has awarded $200,000 to Eric S. Fischer, PhD, of Dana-Farber Cancer Institute to discover new protein degradation targets in gastroesophageal cancer.
January 30, 2024
·
2 min read
Genetown
Harbinger Health Begins New Clinical Study in Individuals at High Risk for Cancer
Harbinger Health (“Harbinger,” “the Company”) announced today a research agreement with the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute to advance the Company’s technology for early-stage multi-cancer detection.
December 5, 2023
·
3 min read
Biotech Beach
Leading Academic Medical Centers Join Biological Dynamics’ ExoLuminate™ Study, Expanding Enrollment for Early Pancreatic Cancer Detection
Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.
December 5, 2023
·
3 min read
Drug Development
Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma
Edgewood Oncology announced the publication of new preclinical data from a study of BTX-A51 in human liposarcoma conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School to be presented at the AACR Annual Meeting 2024 in San Diego.
April 7, 2024
·
4 min read
1 of 30,601
Next